NEW YORK (GenomeWeb) – Benitec Biopharma said this week that laboratory data on the first patient dosed in its Phase I/IIa trial its expressed RNAi treatment for hepatitis C indicate that the drug is safe and well tolerated.
TT-034 is designed to express shRNAs targeting three regions of the HCV genome. The clinical study, which is set to enroll up to 14 HCV patients, began in June.
Benitec also said that a second patient has been identified for dosing in the study, just weeks after disclosing that two potential trial participants had failed to meet its inclusion criteria due to fluctuations in viral load and liver enzymes that were outside of acceptable ranges.
According to the firm, the newly identified patient is currently within the study protocol's clinical parameters and that they will receive TT-034 upon the successful completion of a 28-day screening process.